Tff Pharmaceuticals, Inc. Stock Price, News & Analysis

TFF Pharmaceuticals, in collaboration with Cleveland Clinic, announced the advancement of multiple multivalent universal influenza vaccines into preclinical testing. Utilizing TFF's Thin Film Freezing technology, these vaccines aim to protect against seasonal and pandemic flu viruses. The preclinical testing decision follows successful formulation testing and stability data on hemagglutinin (HA) antigens with four adjuvants. Funded by NIAID, this work aims to create a universal, shelf-stable, and easy-to-transport vaccine, potentially advancing to human clinical trials. The research targets a vaccine that circumvents cold chain storage needs and improves distribution. TFF received a $2.97M SBIR grant in June 2023 for this project, highlighting its potential efficacy and protection against influenza A viruses.

TFF Pharmaceuticals announced an update on its Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for preventing lung transplant rejection. The trial has accelerated patient enrollment with 10 patients currently enrolled. All 6 patients who completed the 12-week treatment have opted to continue to the safety extension phase. One patient has been on treatment for over a year, and three others for more than six months.

The initial pharmacokinetic (PK) data shows reduced systemic variability with TFF TAC, potentially lowering risks of acute rejection and systemic toxicities. Positive feedback includes reduced headaches and improved wellness. A more detailed clinical update is expected later in the year.

TFF Pharmaceuticals (NASDAQ: TFFP) announced its first quarter 2024 financial results, highlighting significant advances in clinical development. The company raised $6.0 million, supporting the progression of its Tacrolimus Inhalation Powder (TFF TAC) for lung transplant recipients. Recent data from the Phase 2 trial showed TFF TAC's potential in preventing organ rejection with favorable safety outcomes. The company submitted a study plan to the FDA and expects feedback in the second quarter. Financially, TFF Pharmaceuticals reported a net loss of $5.7 million, down from $7.1 million in the previous year. R&D expenses decreased by 12%, and G&A expenses fell by 22%. Cash and equivalents stood at $3.2 million as of March 31, 2024.

TFF Pharmaceuticals, Inc (Nasdaq: TFFP) closed a public offering, raising approximately $4.8 million by selling shares and warrants. The company plans to use the net proceeds for general corporate purposes and working capital.

TFF Pharmaceuticals, Inc. announced a public offering of 1,665,219 shares of common stock and warrants, priced at $2.875 per share, with gross proceeds estimated at $4.8 million. The Company plans to use the net proceeds for working capital and general corporate purposes. The offering is expected to close on May 1, 2024.

TFF Pharmaceuticals has released Phase 2 data from Tacrolimus Inhalation Powder (TFF TAC) for preventing lung transplant rejection. Results show TFF TAC can prevent rejection at lower doses than oral tacrolimus, reducing systemic exposures and toxicities. Gene expression data indicate TFF TAC normalizes rejection-related genes, potentially improving efficacy and safety post-transplant.